

**IVI 5th ANNUAL
METHODS SUMMIT**

March 14, 2024 | Washington DC

The Future of Patient-Centered Health Technology Assessment

Participant Worksheet

The IVI Methods Summit aims to bridge the gap between theory and practice by exploring actionable steps that stakeholders can take to implement Patient-Centered Health Technology Assessment (HTA) effectively. Please use this worksheet as a place to add comments, questions, and recommendations. We will use your responses to inform our future work and the meeting summary, and we hope you can use it to foster discussion during each session. Thank you in advance for completing and returning this worksheet.

Health Technology Assessment (HTA) Definition: HTA is defined as an analysis of the clinical and economic value of a particular health care intervention using various factors such as cost, safety, and efficacy. It is used by employers, payers, manufacturers, and policymakers, among others, to help determine how patients are treated and at what cost.

Patient-Centered HTA is characterized by:

1. The core principles of patient-centricity, health equity, and transparency.
2. Authentic partnership with patients (and their families and caregivers) throughout the HTA process, including co-leadership in the process, strategy, and governance, and partnership with decisionmakers in reviewing and applying results.
3. Assurance that patient preferences, patient-centered outcomes and goals, and lived experience help inform HTA methodology (e.g., formation of research questions, model design, and incorporation of evidence) so that assessment models and results reflect what patients value.

Worksheet Questions

Session One – Keynote Discussion. *What are examples of best practices to ensure that the perspectives of patients, family members, and caregivers are incorporated into HTA and modeling?*

Session Two – Equity in Practice. *What are the top steps that need to be taken to improve and promote equity-informed HTA? What role do you see for IVI? What role do you see in your own work?*

Session Three – Real Option Value. *What barriers or opportunities do you think exist to incorporate Real Option Value into the HTA process?*

Definition of Real Option Value: Real Option Value calculates the benefit patients and caregivers receive from treatments that extend life, giving patients the chance to benefit from future treatment advances because of their greater longevity.

(See Other Side)

Please return completed worksheets to IVI at the end of the event. Virtual attendees may send the worksheet to info@thevalueinitiative.org.

Session Four – Rare Disease. What makes patient-centered HTA for rare diseases different, and how can that inform HTA in general?

Session Five – Closing Keynote. What's one thing you would assign yourself or IVI to do to make patient-centered HTA a reality?

What other insights from today's Methods Summit would you like to share?

What stakeholder perspective do you most represent? _____

Please note your name and email if you would like to connect on potential partnership opportunities:

Thank you!

Please return completed worksheets to IVI at the end of the event. Virtual attendees may send the worksheet to info@thevalueinitiative.org.